Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required)

Funding Agency:
National Institutes of Health

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) seeks to support exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors. Projects may include either pediatric or adult cancer patient populations and must identify a treatment-related outcome as a primary endpoint and specify a relevant patient-reported secondary outcome(s). Priority will be given to studies with direct clinical relevance and translational potential. Responsive applications will fill a research gap concerning the efficacy of specific exercise and dietary approaches to improve cancer treatment-related outcomes. Information gained should improve behavioral intervention protocols for cancer survivors undergoing cancer treatment and may also generate feasibility information concerning translation into clinical care. Awardees will participate in an Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium.

Companion FOA: RFA-CA-21-032 , U24 Resource-Related Research Project (Cooperative Agreements)


  • Letter of Intent: June 14, 2021
  • Application: July 14, 2021

RFA-CA-21-031 Expiration Date July 15, 2021

Agency Website

Eligibility Requirements

Each application must have a different PD/PI and distinct research team than an application submitted in response to RFA-CA-21-032 PD/PI.

Amount Description

Application budgets may not exceed $875,000 in direct costs (excluding subaward F&A costs) per year and must reflect the actual needs of the proposed project

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

July 14, 2021